免疫球蛋白重常量玛1沉默降低了对调度有反应的增强剂结合蛋白表达,以缓解糖尿病病症
Qibo Hu1, Qingxiao Yang2, Hang Gao3
1Department of Pediatrics, The Second Hospital of JiLin University, Changchun, China.
Journal of diabetes investigation
|January 25, 2024
概括
沉默免疫球蛋白重常量玛1 (IGHG1) 通过抑制TRIM11/MEK/ERK通路和降低TonEBP的调节来缓解糖尿病病. 这一发现为糖尿病病提供了潜在的治疗标.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 糖尿病病 (DN) 的机制尚未完全理解.
- 微阵列数据提供了对DN病变发生的洞察.
- 生物信息学方法可以识别DNA中的关键分子参与者.
研究的目的:
- 使用生物信息学探索糖尿病病的分子机制.
- 为了识别与DN相关的枢纽基因.
- 研究免疫球蛋白重常数玛1 (IGHG1) 在DNA发育中的作用.
主要方法:
- 生物信息学分析以选DNA中的枢纽基因.
- 在体外细胞模型中,使用暴露于高葡萄糖的人类管状上皮细胞.
- 在体内小鼠模型中,DN是由高脂肪饮食和 estreptozotocin 诱导的.
- 在体外和体内,shRNA介导的IGHG1沉默.
主要成果:
- 确定IGHG1,TRIM11和TonEBP在DN中表达很高.
- 在高葡萄糖条件下,IGHG1积极调节TRIM11和TonEBP的表达.
- TRIM11通过MEK/ERK信号通道调节了TonEBP.
- 沉默IGHG1可以在体内防止DN的发生和进展.
结论:
- 抑制IGHG1通过抑制TRIM11/MEK/ERK轴来减轻DN.
- 降低TonEBP的调节是IGHG1沉默在DN.中的一个关键效应.
- IGHG1是糖尿病病的潜在治疗标.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
577
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
160
相关概念视频
01:58Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
01:16TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K